PAS-LAR treatment (appendix). This increase was particularly substantial (>50%) in eight patients, where the majority of the adenoma became T2-hyperintense (figure). In general, a hyperintense T2 signal indicates cystic degeneration, tumour cell necrosis, or both, which suggests an antitumour effect of PAS-LAR. T2 hyperintensity was found in ten of 47 patients within 9 months of PAS-LAR treatment, and in four additional patients after the end of the study (median 29·5 months [IQR 11·4-35·4] of PAS-LAR treatment). Post-study MRI (median 32·4 months [IQR 31·3-33·5] after study end) was also done in two of the first ten patients. In these patients, the T2-weighted MRI signal remained hyperintense in the adenoma of one patient (after 31 months of PAS-LAR treatment) and increased further in the adenoma of the second (after 33 months of PAS-LAR treatment).
At the end of the study, the mean T2-signal intensity ratio in the total cohort (n=47) during PAS-LAR treatment was significantly higher than baseline (1·42 [ The PAPE study, 3,4 which investigated patients with acromegaly who were well controlled on a combination of first-generation somatostatin receptor ligands and the growth hormone receptor antagonist pegvisomant, indicated that switching to PAS-LAR resulted in control of IGF-1 concentrations in most patients. In this follow-up analysis of patients from the PAPE study, we assessed 47 patients for T2-weighted signal by MRI (appendix) . Surprisingly, the T2-weighted MRI signal of the adenoma was increased (mean increase 1·71 [SD 0·62]) in 14 (30%) of 47 patients 3,4 during
